Engflag

Nefidipine

Quick links to important sections

Nefidipine

Nefidipine_PL

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nefidipine

Quick Facts about Nifedipine

Property Description
Active Ingredient Nifedipine (INN)
Form Oral Solid (Capsules, Tablets, Extended-Release Tablets)
Pharmacological Class Calcium Channel Blocker (CCB)
Common Use Antihypertensive Agent
Origin Synthetic Compound

Defining Nifedipine: Class, Composition, and Origin

Nifedipine, sometimes referenced by the variant spelling Nefidipine, is a synthetic, single-ingredient medication belonging to the pharmacological class known as Calcium Channel Blockers (CCBs). Its official designation is the International Nonproprietary Name (INN) Nifedipine. Specifically, Nifedipine is classified as a Dihydropyridine derivative which defines its primary action site on the body's vascular system. The active ingredient is a chemically manufactured substance, compounded with pharmaceutical excipients to create the final oral dosage forms. This classification as a dihydropyridine is clinically recognized for its potent vascular selectivity, focusing its mechanism largely on the blood vessel walls.

What is the General Therapeutic Purpose of this Dihydropyridine?

The general therapeutic purpose of Nifedipine is to function as an effective antihypertensive agent by reducing muscular tension in blood vessel walls. Its core action promotes vasodilation (widening of blood vessels) by interfering with the movement of calcium ions. This mechanism helps reduce the force the heart must exert to move blood. By achieving this reduction in resistance, the medication eases the workload on the heart and improves overall circulation, making it a cornerstone in long-term management strategies. Nifedipine is designed for oral administration in solid dosage forms, including both immediate-release capsules and specialized extended-release tablets, offering flexibility for achieving consistent, prolonged therapeutic effect.

Regulatory References

  1. MedlinePlus

What side effects are possible with Nefidipine?

Possible Side Effects and Safety Information

The official safety profile for Nifedipine, a dihydropyridine calcium channel blocker, includes adverse reactions categorized by frequency and system-organ class, derived from regulatory prescribing information. The most common adverse reactions are expressions of its vasodilatory action, primarily involving the cardiovascular and nervous systems.

Adverse Reaction Classifications

The most frequently documented effects include peripheral edema (swelling, particularly of the lower limbs), flushing, and headache. Other reactions, reported with a lower incidence (le 3% in clinical trials), affect systems such as the central nervous system (e.g., dizziness, paresthesia), the gastrointestinal system (e.g., constipation, gum disorder), and the musculoskeletal system (e.g., leg cramps).

Serious Adverse Reactions and Restrictions

Regulatory documents highlight serious adverse reactions that occur rarely, including increased angina and/or myocardial infarction, excessive hypotension, and congestive heart failure. Rare instances of clinically apparent hepatocellular or mixed-pattern liver injury have also been reported.

Official labeling defines specific safety limitations. Nifedipine is contraindicated in patients with cardiogenic shock or those concomitantly using strong CYP3A4 enzyme inducers (such as rifampin). Additionally, co-administration of grapefruit or grapefruit juice must be avoided as it significantly increases systemic drug exposure.

Population and Time-Related Safety

Specific safety considerations exist for certain populations. Safety and efficacy have not been established in the pediatric population. Caution is advised for patients with hepatic impairment. The immediate-release formulation is officially avoided in the older adult population due to heightened risk of hypotension and myocardial ischemia. Time-related patterns show that vasodilatory effects, such as dizziness, are more likely to occur when beginning treatment or when the dose is increased.

Overdose and Emergency Response

Overdose and when to seek help

Overdosage with Nifedipine is officially described as resulting in a significant extension of its intended effects, potentially leading to profound hypotension and circulatory failure.

Documented Manifestations and Severe Outcomes

Category Description from Regulatory Sources
Primary Manifestations Disturbances of consciousness, including loss of consciousness or coma, bradycardia (slow heart rate), tachycardia (fast heart rate), hyperglycemia, nausea, and vomiting.
Severe Outcomes Cardiogenic shock, pulmonary oedema, and death have been reported, particularly associated with the use of immediate-release forms for acute pressure reduction.
Specific Population Notes Clearance is expected to be prolonged in patients with impaired liver function.

Emergency Action and Management

Pronounced hypotension due to overdosage mandates active cardiovascular support. Immediate emergency medical help must be sought if the individual has collapsed, had a seizure, has trouble breathing, or can't be awakened.

Documented supportive measures include the judicious use of calcium infusion and administration of pressor agents (vasopressors) to manage severe physiological instability. Due to the high protein-binding of the drug, dialysis is not likely to be of any benefit. Monitoring of cardiovascular and respiratory function is required for ongoing stabilization.

Therapeutic Uses of Nefidipine

What Nifedipine Treats: Main Uses and Benefits

Nifedipine is commonly used in therapeutic areas involving the management of high blood pressure and certain types of angina pectoris.

The primary uses include the long-term management of essential hypertension, addressing the chronic condition of elevated systemic arterial pressure, and providing symptomatic support for angina pectoris (recurrent chest discomfort), including chronic stable and vasospastic forms. It is also relevant for conditions associated with severe symptoms related to heightened physiological activity in the extremities, such as Raynaud's phenomenon.

Symptom Management and Patient Support

Nifedipine is commonly used in settings marked by temporary physiological imbalance or increased systemic burden. The key benefit is sustained pressure control, which supports the management of cardiovascular strain and may assist in reducing the burden of conditions associated with elevated blood pressure. The medication assists with maintaining functional stability by helping to ease the overall symptom load during episodes of discomfort.

Quick Fact: Symptomatic Support in Key Domains

Therapeutic Focus Symptom Category Addressed Patient Benefit
Hypertension Symptoms related to systemic imbalance Contributes to improved comfort during symptomatic periods
Angina Pectoris Symptoms related to physical discomfort Helps patients cope more steadily with episodes
Peripheral Disorders Symptoms of increased physiological activity Assists with maintaining functional stability in extremities

Eligibility and Restrictions for Use

Who Can and Cannot Use Nifedipine

The eligibility profile for Nifedipine is defined by regulatory bodies to outline specific patient populations who can and cannot use the medicine.

Populations for Whom Use is Contraindicated

Nifedipine is formally contraindicated and must not be used in several conditions, including cardiogenic shock, and in patients with a known hypersensitivity to nifedipine or any other dihydropyridine. Additionally, European labels often prohibit use during unstable angina or within one month of a myocardial infarction. The medication is also strictly contraindicated when taken alongside the strong CYP3A4 inducer Rifampicin.

Age and Physiological Restrictions

Population Group Eligibility Status
Pediatric (Under 18) Use is not established and generally not recommended due to insufficient data.
Older Adults (Geriatric) The Immediate-Release formulation should be avoided (risk of excessive hypotension).
Pregnancy Often contraindicated by regulatory bodies unless strictly necessary.
Lactation Not recommended as the medicine is excreted into breast milk.

Conditional Use Requirements

Use requires caution and close monitoring in patients with severe hepatic impairment due to altered drug clearance. Extended-release formulations are also contraindicated in patients with conditions that cause gastrointestinal narrowing or a Kock pouch.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Nifedipine's interaction profile, documented in official regulatory sources, is defined by its metabolic clearance and pharmacodynamic effects.

Contraindicated Combinations and Restrictions

The co-administration of Rifampicin (Rifampin) is strictly contraindicated. This is because Rifampicin is a strong enzyme inducer that causes a distinct reduction in Nifedipine’s plasma levels, leading to a risk of therapeutic failure. Ingestion of Grapefruit or Grapefruit juice must also be avoided, as documented regulatory data shows it significantly increases Nifedipine's systemic exposure.

Officially Documented Interaction Patterns

The most common mechanism of drug interaction involves the CYP3A4 metabolic pathway. Concomitant use with strong CYP3A4 inhibitors (e.g., certain Macrolide antibiotics or anti-HIV protease inhibitors) results in increased Nifedipine plasma concentrations due to reduced clearance. Conversely, strong CYP3A4 inducers (e.g., Phenytoin, Carbamazepine) decrease Nifedipine exposure.

Additionally, Nifedipine exhibits a pharmacodynamic interaction with Beta-blockers and other antihypertensives, resulting in an additive blood pressure-lowering effect which may increase the risk of severe hypotension. Nifedipine also causes elevated serum concentrations of Digoxin by reducing its clearance, a transporter-based effect noted in prescribing information.

Mechanism of Action

How Nifedipine Works

Nifedipine's core mechanism centers on the selective inhibition of Voltage-Gated L-Type Calcium Channels ( Ca v1), which are predominantly located on the muscle cells lining the arterial walls. This mechanistic action is characterized by voltage dependence, where Nifedipine functions as a blocker, preventing the influx of extracellular calcium ions ( Ca^2+) into the cells.

Blocking the Excitation-Contraction Cascade

By blocking Ca^2+ entry, Nifedipine interrupts the cellular signaling sequence required to activate the muscle's contractile machinery. This leads to the inhibition of key enzymes like Myosin Light-Chain Kinase, which prevents the essential actin-myosin cross-bridge formation. This modification of early molecular steps results in the direct relaxation of the arterial wall, engaging mechanisms that modulate contractile processes.

Regulating Arterial Tone and Systemic Resistance

This cellular relaxation translates into widespread vasodilation (widening of the arteries) and a resulting decrease in Systemic Vascular Resistance (SVR). This physiological consequence reduces the external resistance against which the heart pumps (afterload), leading to predictable hemodynamic changes that result in reduced tension within the vascular pathways.

Dosage and Administration Information

How to Use Nifedipine: Administration Guidelines

Nifedipine is administered through the oral route using two primary dosage forms: Immediate-Release (IR) capsules and various Extended-Release (ER) tablets. The specific formulation determines the required frequency and method of use.

Administration Frequency and Dosing Principles

Feature Guideline
Dosing Schedule (ER) Typically administered once daily (QD). Initial doses often start at 30 mg or 60 mg. Maintenance doses range from 30 mg to 90 mg once daily.
Dosing Schedule (IR) Requires divided doses, generally taken three or four times per day, due to its shorter duration of action. Initial dose is often 10 mg three times daily.
Dose Titration Doses are generally adjusted incrementally, usually every 7 to 14 days, based on the therapeutic response, up to the established maximum daily limits.
Timing in Relation to Meals Can be taken with or without food. However, some specific extended-release formulations are advised to be taken consistently on an empty stomach (e.g., 1 hour before or 2 hours after a meal).

Special Procedural Instructions

Extended-release tablets must be swallowed whole with a sufficient quantity of liquid. It is a strict procedural requirement that these tablets are not chewed, crushed, or divided, as altering the form compromises the controlled-release mechanism.

For older adults and individuals with hepatic impairment, a lower initial starting dose is often utilized. Dose adjustments are made cautiously and gradually in these populations due to potential alterations in the body's processing of the medicine. If a dose is missed, it should be taken as soon as possible, unless it is nearly time for the next scheduled dose, in which case the missed dose is skipped.

Recent Clinical Evidence

Research evidence / Overview of studies for Nifedipine

The research base for Nifedipine is primarily defined by large Randomized Controlled Trials (RCTs) and systematic Meta-analyses that have explored its use in specific cardiovascular and circulatory conditions. The evidence describes patterns observed in these studies, focusing on changes in physiological measures and symptom evolution. Research for Nifedipine has yielded evidence that is broadly categorized as High regarding the consistency of measured physiological changes, and Moderate for long-term outcomes in certain complex conditions.

Evidence for use in Essential Hypertension

Research has extensively explored Nifedipine’s use in Adults with Mild to Moderate Hypertension. Studies monitored changes in the key outcomes: Systolic and Diastolic Blood Pressure, and the occurrence of serious Cardiovascular Events. Findings describe patterns consistently reporting measurements related to changes in blood pressure. Studies monitored outcomes related to cardiovascular events; research data for the sustained-release formulations was observed in studies where the medication was used as part of a multi-drug regimen.

Evidence for use in Angina Pectoris

Nifedipine was evaluated in studies for Angina Pectoris. Research examined outcomes related to Anginal Episode Frequency and the use of required rescue medications. Studies report how symptoms evolved in the observed populations, with trials reporting measurements related to changes in the number of anginal episodes. However, certain analyses described patterns suggesting that immediate-release monotherapy was associated with a potential for increased angina episodes in some observed populations.

Areas of Research Uncertainty and Gaps

A key area of uncertainty relates to the distinction between the different formulations. Findings indicate that the immediate-release form was associated with specific patterns observed in some studies. Research efforts have been observed to primarily focus on the sustained-release versions in studies exploring long-term use. For conditions like peripheral disorders, the existing research is constrained because sample sizes were modest and follow-up durations were limited, restricting certainty about sustained effects. Long-term effects across all indications and population groups are not fully established.

Frequently Asked Questions (FAQ)

Common questions about Nefidipine (FAQ)

Q: What should I do if I miss a dose of Nifedipine?

If a dose is missed, official guidance suggests taking it as soon as it is remembered. However, if it is nearly time for the next scheduled dose, regulatory documents advise that the missed dose be skipped and the regular schedule resumed. It is important not to take a double dose to compensate for the missed one.

Q: How is the Nifedipine dose adjusted by the doctor?

Doses are adjusted based on the therapeutic response to the medicine, as determined by a healthcare provider. Official dosing guides indicate that adjustments are typically made incrementally every 7 to 14 days. This allows enough time to evaluate the full clinical effects before a change is made.

Q: Is it safe to take Nifedipine if I am pregnant or breastfeeding?

Regulatory documents state that use during pregnancy is often contraindicated unless a healthcare provider determines the potential benefit significantly outweighs the potential risk to the fetus. The medication is generally not recommended while breastfeeding. The decision to use this medicine during pregnancy or lactation should be made by a healthcare provider after weighing the risks and benefits.

Q: What is Nifedipine used for?

According to official product information, Nifedipine is indicated for managing chronic stable angina (chest pain with effort) and vasospastic angina (a type of chest pain caused by artery spasm). Extended-release formulations are also commonly approved for the treatment of hypertension (high blood pressure).

Q: Can Nifedipine be used to treat Raynaud’s phenomenon or other peripheral circulatory disorders?

Nifedipine is licensed in certain regions for the treatment of Raynaud's phenomenon, a condition affecting blood flow to the extremities. In other areas, while not formally labeled for this use, it may be used off-label based on clinical guidelines. The decision to use it for peripheral circulatory disorders is made by a healthcare provider.

Q: What is the onset of action for Nifedipine immediate-release (how fast does it work)?

Pharmacokinetic data from regulatory sources shows that the immediate-release form of Nifedipine is absorbed rapidly. The drug begins to appear in the bloodstream within approximately 10 minutes, reaching its peak concentration around 30 minutes after taking it. The timing suggests a rapid onset of activity, which is reflected in clinical use.

Q: How do I dispose of expired or unused Nifedipine if a take-back program isn't available?

If a medicine take-back program is unavailable, official disposal guidelines recommend removing the Nifedipine from its original container. The recommendation is to mix the medicine with an undesirable substance, such as used coffee grounds or kitty litter. This mixture should then be sealed in a plastic bag or container before being placed in the household trash.

How should Nefidipine be stored and disposed of?

How to Store and Dispose of Nifedipine

Nifedipine requires specific handling conditions as mandated by regulatory documents to preserve its stability.

Storage Requirements

  • Temperature: Immediate-release capsules must be stored at Controlled Room Temperature (20 C to 25 C), while extended-release tablets must be stored at temperatures not exceeding 30 C.
  • Protection: The medicine must be protected from light and moisture.
  • Container: Store in the original container, which must be kept tightly closed.
  • Safety: The medication must be kept securely out of the sight and reach of children and pets.

Disposal Instructions

Unused or expired Nifedipine should be disposed of through a medicine take-back program if available. If a take-back option is not accessible, the product must be mixed with an unappealing substance and sealed in a container before being placed in the household trash. Nifedipine is not on the official list of medicines recommended for flushing.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Nefidipine found in:

A-Z Index: